ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,181 to 3,200 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Physical Therapy106 of 1,192

77 of 1,069

1.7 points

-0.6 to 3.9

2,261NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

GBC+PIPT vs Guideline Based Care: Number of Patients Undergoing Interventional Pain Procedures32 of 1,192

43 of 1,069

-1.3 points

-2.9 to 0.1

2,261NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Surgery Specialist38 of 1,192

44 of 1,069

-0.9 points

-2.5 to 0.6

2,261NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

GBC+PIPT vs Guideline Based Care: Number of Patients Who Had Back Surgery29 of 1,192

19 of 1,069

0.7 points

-0.6 to 1.9

2,261NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

GBC+PIPT vs Guideline Based Care: Number of Patients Prescribed Opioids89 of 1,192

86 of 1,069

-0.6 points

-2.8 to 1.6

2,261NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

GBC+PIPT vs Guideline Based Care: Number of Patients With Orders for Diagnostic Imaging Tests74 of 1,192

73 of 1,069

-0.6 points

-2.7 to 1.4

2,261NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Other Rehabilitation or Pain Management Specialist45 of 1,192

26 of 1,069

1.3 points

-0.1 to 2.8

2,261NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

Seqirus Quadrivalent Influenza Vaccine vs Comparator Quadrivalent Influenza Vaccine: Safety Endpoint: The Frequency of Serious Adverse Events (SAEs).8 of 1,692

2 of 560

0.1 points

-0.8 to 0.6

2,252NCT02545543

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

Seqirus Quadrivalent Influenza Vaccine vs Comparator Quadrivalent Influenza Vaccine: serious adverse events8 of 1,692

2 of 560

0.1 points

-0.8 to 0.6

2,252NCT02545543

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

Pneumosil vs Synflorix: deaths from any cause1 of 1,503

2 of 747

-0.2 points

-0.9 to 0.2

2,250NCT03197376

Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants

Pneumosil vs Synflorix: serious adverse events51 of 1,503

26 of 747

-0.1 points

-1.9 to 1.4

2,250NCT03197376

Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants

Vedolizumab 300 mg (UC) vs Vedolizumab 300 mg (CD): Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) Findings7 of 894

7 of 1,349

0.3 points

-0.4 to 1.1

2,243NCT00790933

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

Fosaprepitant vs Aprepitant: A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).795 of 1,106

820 of 1,134

-0.4 points

-4.1 to 3.3

2,240NCT00619359

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

No Text Message Reminder (Control) Arm vs Text Message Reminder Arm: Attendance at Breast Screening661 of 1,118

722 of 1,122

-5.2 points

-9.2 to -1.2

2,240NCT01977599

Are Text Message Reminders an Effective Intervention for Improving the Uptake of Breast Screening?

No Text Message Reminder (Control) Arm vs Text Message Reminder Arm: Mobile Prevalence435 of 1,118

456 of 1,122

-1.7 points

-5.8 to 2.3

2,240NCT01977599

Are Text Message Reminders an Effective Intervention for Improving the Uptake of Breast Screening?

Fosaprepitant vs Aprepitant: A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).822 of 1,106

841 of 1,133

0.1 points

-3.5 to 3.7

2,239NCT00619359

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

Golytely vs Miralax-Gatorade Prep: Population Level Adenoma Detection Rate (ADR)383 of 1,139

364 of 1,100

0.5 points

-3.4 to 4.4

2,239NCT03298945

Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens

Golytely vs Miralax-Gatorade Prep: Cancellation or No-show in Each Bowel Prep Arm358 of 1,139

330 of 1,100

1.4 points

-2.4 to 5.2

2,239NCT03298945

Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens

Golytely vs Miralax-Gatorade Prep: Colonoscopy Completion Rate591 of 1,139

600 of 1,100

-2.7 points

-6.8 to 1.5

2,239NCT03298945

Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens

Golytely vs Miralax-Gatorade Prep: deaths from any cause7 of 1,139

4 of 1,100

0.3 points

-0.4 to 0.9

2,239NCT03298945

Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=160"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=160

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02647658-0c9f8424",
        "title": "GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Physical Therapy",
        "summary": "106 of 1192 against 77 of 1069; risk difference 1.7 points, 95% interval -0.6 to 3.9; NCT02647658, Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients",
        "record": "/library/comparisons/NCT02647658-0c9f8424",
        "nct_id": "NCT02647658",
        "kind": "outcome",
        "participants": 2261,
        "risk_difference": {
          "value": 0.01689623997840295,
          "lower": -0.005746110926008151,
          "upper": 0.03932126138473607
        },
        "group_1": "106 of 1,192",
        "group_2": "77 of 1,069",
        "difference": "1.7 points",
        "interval": "-0.6 to 3.9",
        "trial_title": "Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients"
      },
      {
        "id": "NCT02647658-59d09f01",
        "title": "GBC+PIPT vs Guideline Based Care: Number of Patients Undergoing Interventional Pain Procedures",
        "summary": "32 of 1192 against 43 of 1069; risk difference -1.3 points, 95% interval -2.9 to 0.1; NCT02647658, Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients",
        "record": "/library/comparisons/NCT02647658-59d09f01",
        "nct_id": "NCT02647658",
        "kind": "outcome",
        "participants": 2261,
        "risk_difference": {
          "value": -0.013378871302917487,
          "lower": -0.028969265754322,
          "upper": 0.0014985711559636263
        },
        "group_1": "32 of 1,192",
        "group_2": "43 of 1,069",
        "difference": "-1.3 points",
        "interval": "-2.9 to 0.1",
        "trial_title": "Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=161",
  "request_id": "-OBe1-CMj18La5A0"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?